Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 603 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EX Clear all
Terminated Phase 1 Interventional

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

NCT01312376
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 20, 2026, 1:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complement C5a Receptors in Hidradenitis Suppurativa

NCT04251663
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 20, 2026, 1:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Lungs of Normal Individuals by Lung Lavage, Brushing and Bronchial Wall Biopsy

NCT00224185
View directory record Official record
Conditions
Smoking, Lung Diseases
Interventions
Bronchopulmonary Lung Lavage, Bronchial Brushing, Bronchial Wall Biopsy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 20, 2026, 1:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05460533
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Day to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Completed No phase listed Observational

Clinical Implications of Peripheral Plaque Morphology

NCT00578422
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ivus (Intravascular Ultrasound) of Amputation Specimens, IVUS (Intravascular Ultrasound)
Other · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Recruiting Phase 3 Interventional

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

NCT04722692
View directory record Official record
Conditions
DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions
Delayed SLND, Late SLND
Diagnostic Test
Lead sponsor
Uppsala University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 20, 2026, 1:06 AM EDT
Recruiting Phase 1 Interventional

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

NCT03533816
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
Interventions
EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Westwood, Kansas • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1 Interventional Results available

T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

NCT01210664
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 20, 2026, 1:06 AM EDT
Terminated Phase 1 Interventional Results available

Autologous Polyclonal Tregs for Lupus

NCT02428309
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 20, 2026, 1:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity

NCT01867411
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acamprosate and Methazolamide for Essential Tremor

NCT06312800
View directory record Official record
Conditions
Essential Tremor
Interventions
Acamprosate, Placebo, Methazolamide
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

NCT05795595
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Interventions
CTX131
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

NCT01866839
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymphoma, Non-Hodgkin, ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia
Interventions
Graft Manipulation (CD34+ Selection)
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 20, 2026, 1:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictors of Sepsis in Ex-Preterm Infants

NCT03433846
View directory record Official record
Conditions
Sepsis, Premature Birth
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 2 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 2 Interventional

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

NCT00877903
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Prochymal®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
32
States / cities
Gilbert, Arizona • Tucson, Arizona • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Early Phase 1 Interventional

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

NCT07144384
View directory record Official record
Conditions
Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Natural Killer Cell Therapy, Surgical Procedure, Universal Donor Expanded TGF-beta-imprinted NK Cells
Procedure · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

NCT00374933
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1 Interventional

Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

NCT00114452
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Provacel, Placebo
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 20, 2026, 1:06 AM EDT
Not yet recruiting Phase 2 Interventional

DOSE-UP: Dose Optimization for Smoking and E-Cigarette Use Pharmacotherapy

NCT07754578
View directory record Official record
Conditions
Dual Use of Cigarettes and E-cigarettes
Interventions
Text- and web-based support, Nicotine Replacement Therapy (NRT, nicotine patch), Nicotine replacement therapy lozenge
Behavioral · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Terminated Not applicable Interventional

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides

NCT03789864
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Interventions
Biodynamic imaging (BDI) of mycosis fungoides
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 20, 2026, 1:06 AM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

NCT03818763
View directory record Official record
Conditions
Hemophilia A
Interventions
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Active, not recruiting Phase 1 Interventional

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

NCT07031765
View directory record Official record
Conditions
Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV Astrocytoma
Interventions
exHSC, Nivolumab, Resection or biopsy
Biological · Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 26 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 1:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 1:06 AM EDT